1940P - A novel RAF/MEK inhibitor CH5126766 in phase I clinical trial has an effectiveness in the combination with eribulin for the treatment of triple negative breast cancer
| Autor: | Ono, H. 1, Horinaka, M. 1, Yasuda, S. 1, Morita, M. 1, Nishimoto, E. 1, Sakai, T. 1 |
|---|---|
| Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v782-v782 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|